과학기자재전시실 | 견적의뢰 | 미등재상품상담 | 수출입 및 제조상담 | 실험상담 | 협력업체문의
(Technical References) EpiVaginal Tissue Model
 

 
  →  상품상세정보  

 

Technical References ( EpiVaginal )

 

 

724. DEVELOPMENT OF A COMBINATION MICROBICIDE GEL FORMULATION CONTAINING IQP-0528 AND TENOFOVIR FOR THE PREVENTION OF HIV INFECTION.

Ham1, A.S., Ugaonkar2, S.R., Shi3, L., Watson Buckheit1, K., Lakougna2,H., Nagaraja2, U., Gwozdz3, G., Goldman3, L., Kiser2,4, P.F., Buckheit1, R.W.Jr.  1ImQuest BioSciences, Frederick, Maryland 21704, 2Department of Bioengineering, University of Utah, Salt Lake City, Utah 84112, 3Particle Sciences, Bethlehem, Pennsylvania 18017, 4Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah 84112. J Pharm Sci, 101, 1423–1435 (2012).

 

716. SIMULTANEOUS DETECTION AND SEMIQUANTIFICATION OF DNA DAMAGE IN NORMAL AND APOPTOTIC CELLS: TRIPLE-IMMUNOFLUORESCENT LABELING USING DAPI, ANTIBODIES, AND TUNEL.

Agrawal, A. and Godar, D.E. US Food and Drug Administration, Center for Devices and Radiological Health, Silver Spring, MD. Appl Immunohistochem Mol Morphol, 20, 4, (2012).

 

714. ENHANCED ANTIVIRAL ACTIVITY OF ACYCLOVIR LOADED INTO NANOPARTICLES.

Cavalli1, R., Donalisio2, M., Bisazza1, A., Civra2, A., Ranucci3, E., Ferruti3, P. and Lembo2, D. 1Dipartimento di Scienza e Tecnologia del Farmaco, Universita` di Torino, Torino, Italy. 2Dipartimento di Scienze Cliniche e Biologiche, Universita` di Torino, Torino, Italy. 3Dipartimento di Chmica Organica e Industriale, Universita` degli Studi di Milano, Milano, Italy. Methods in Enzymology, 509, (2012).

 

712. PRECLINICAL EVALUATION OF ANTI-HIV MICROBICIDE PRODUCTS: NEW MODELS AND BIOMARKERS.

Doncel, G.F., Clark, M.R. CONRAD, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA.  Antiviral Research, 88S, S10–S18 (2010).

 

710. VAGINAL MICROBICIDE GEL FOR DELIVERY OF IQP-0528, A PYRIMIDINEDIONE ANALOG WITH A DUAL MECHANISM OF ACTION AGAINST HIV-1.

Mahalingam1, Simmons2, A.P., Ugaonkar2, S.R., Watson3, K.M., Dezzutti4, C.S., Rohan4, L.C., Buckheit3, Jr., R.W.  and Kiser1,2, P.F.  1Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah; 2Department of Bioengineering, University of Utah, Salt Lake City, Utah; 3ImQuest BioSciences, Inc., Frederick, Maryland; and 4Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Magee-Womens Research Institute, Pittsburgh, Pennsylvania. Antimicrobial Agents and Chemotherapy, 55, 4, 1650–1660 (2011).

 

709. ACTIVITY AND SAFETY OF SYNTHETIC LECTINS BASED ON BENZOBOROXOLE-FUNCTIONALIZED POLYMERS FOR INHIBITION OF HIV ENTRY.

Mahalingam1, A., Geonnotti2, A.R., Balzarini3, J. and Kiser1, P.F.  1Departments of Pharmaceutics and Pharmaceutical Chemistry and Bioengineering, University of Utah, Salt Lake City, Utah, U.S. 2Duke University Medical Center, Durham, North Carolina, U.S.  3Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Molecular Pharmaceutics, 8, 2465-2475, (2011).

 

699. ASSESSMENT OF AN IN VITRO HUMAN VAGINAL EPITHELIAL MODEL FOR PREDICTING VAGINAL IRRITATION.

Evans1, E.B., Priston1, R., Willoughby2, J.A. Sr., Wagner2,  H.N. and McKim2, J.M. Jr. 1Kimberly-Clark Corporation, Roswell, GA.  2Ceetox, Inc., Kalamazoo, MI.   Presented at SOT 2012, Abstract 1816.

 

685. ANTI-GP120 MINIBODY GENE TRANSFER TO FEMALE GENITAL EPITHELIAL CELLS PROTECTS AGAINST HIV-1 VIRUS CHALLENGE IN VITRO.

Abdel-Motal1, U.M., Sarkis1, P.T.N., Han1, T., Pudney2, J., Anderson2, D.J., Zhu1, Q., Marasco1, W.A.  1Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, 2Department of Obstetrics and Gynecology, School of Medicine, Boston University, Boston, Massachusetts, United States of America.

 

671. PREVENTION OF VAGINAL SHIV TRANSMISSION IN MACAQUES BY A LIVE RECOMBINANT LACTOBACILLUS.

Lagenaur1,2, L.A., Sanders-Beer3, B.E., Brichacek1, B., Pal4, R., Liu2, X. Liu2, Y., Yu5, R., Venzon6, D., Lee2, P.P., and Hamer1, D.H.  1Gene Structure and Regulation Section, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 2Osel, Mountain View, California, USA. 3BIOQUAL, Rockville, Maryland, USA. 4Advanced BioScience Laboratories, Rockville, Maryland, USA. 5Cepheid, Sunnyvale, California, USA. 6Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA. Mucosal Immunology, advance online publication 6 July 2011, doi:10. 10.8/mi.2011.30.

 

665. PRECLINICAL EVALUATION OF UC781 MICROBICIDE VAGINAL DRUG DELIVERY.

Clark1, M.R., McCormick2, T.J., Doncel3, G.F., and Friend1, D.R.  Department of Obstetrics and Gynecology, Eastern Virginia Medical School, 1Arlington VA, 2West Chester PA, 3Norfolk VA  Drug Deliv. and Transl. Res.,  1:175–182 (2011).

 

664. TRANSFER OF IgG IN THE FEMALE GENITAL TRACT BY MHC CLASS I-RELATED NEONATAL FC RECEPTOR (FCRN) CONFERS PROTECTIVE IMMUNITY TO VAGINAL INFECTION.

Li1,2, Z.,Palaniyandi1,2, S., Zeng1,2, R.,Tuo3, W., Roopenian4, D.C., and Zhu1,2, X.  1Laboratory of Immunology, Virginia-Maryland Regional College of Veterinary  Medicine, College Park, MD 20742; 2Maryland Pathogen Research Institute, University of Maryland, College Park, MD 20742; 3Animal Parasitic Diseases Laboratory, Agricultural Research Service, United  States Department of Agriculture, Beltsville, MD 20705; and 4The Jackson Laboratory, Bar Harbor, ME 04609. PNAS, 108, (11), 4388-4393, (2011).

 

662. HYDROGEN PEROXIDE MEDIATED TRANSVAGINAL DRUG DELIVERY.

Fatakdawala, H., Uhland, S.A. Palo Alto Research Center, Palo Alto, CA 94304, United States. Inter. J. of Pharmaceutics, 409, 121-127, (2011).

 

656. EPIVAGINAL TISSUE MODEL FOR PRECLINICAL SCREENING OF SINGLE OR REPEAT EXPOSURE TO VAGINALLY APPLIED CHEMICALS/FORMULATIONS.

Ayehunie, S., Cannon, C., LaRosa, K., Landry, T., Wang, A., and Klausner, M. MatTek Corporation, Ashland, MA, USA. Presented at SOT 2011, Abstract #1049.

 

643. IDENTIFICATION OF ENDOCRINE DISRUPTORS USING AN ORGANOTYPIC VAGINAL TISSUE MODEL.

Ayehunie, S., Landry, T., LaRosa, K., Klausner, M.,  and Sheasgreen, J.  MatTek Corporation, Ashland, MA, USA.  Presented at SOT 2011, Abstract #2373.

 

639. ASSESSMENT OF ORGANOTYPIC EPIVAGINALTM TISSUE MODEL TO SCREEN IRRITATION POTENTIAL OF CHEMICALS.

Ayehunie, S., Kaluzhny, Y., Cannon, C., LaRosa, K., Klausner, M.  MatTek Corporation, Ashland, MA. Presented at 49th Annual SOT Meeting, Salt Lake City, Utah (2010).

 

624. DEVELOPMENT OF AN IN VITRO ALTERNATIVE ASSAY METHOD FOR VAGINAL IRRITATION.

Ayehunie1, S., Cannon1, C., LaRosa, K., Pudney2, J., Anderson2, D.J., Klausner1, M. 1MatTek Corporation, 200 Homer Avenue, Ashland, MA 01721, United States. 2Department of Obstetrics and Gynecology and Microbiology, Boston University School of Medicine, Boston, MA, United States. Toxicology, Article in press (2010) Toxicology, Article in press (2010).

 

621. GENOTOXICITY TESTING USING THE NORMAL HUMAN CELL BASED 3D EPITHELIAL MODELS.

Kaluzhny, Y., Karetsky, V., DeLuca, J., Armento, A., Hayden, P., Ayehunie, S. and Klausner, M. MatTek Corporation, Ashland, MA, USA. IIVS In Vitro Alternatives Forum, October 2010.

 

611. IN VITRO ASSESSMENT OF PERSONAL CARE PRODUCTS FOR VAGINAL IRRITATION USING 3D TISSUE CONSTRUCTS.

Evans1, E., Priston1, R., Inglis2, H., Barnes2, N., Raabe2, H., Costin2, G.-E. 1The Kimberly-Clark Corporation, Roswell, GA, USA. 2Institute for In Vitro Sciences, Inc. (IIVS), Gaithersburg, MD, USA. Presented at Society of Toxicology Meeting, Salt Lake City, UT March 2010.

 

577. SAFETY TESTING OF SILICONE ELASTOMER MATRIX VAGINAL RINGS CONTAINING UC781 AND TWEEN 80 USING EPIVAGINAL(VEC-606) TISSUES.

McConville1, C., Woolfson1, A.D., Elgendy2, H., Friend2, D., Malcolm1, R.K. 1School of Pharmacy, Queens University of Belfast, Belfast, UK 2CONRAD, Arlington, VA, USA. Presented at Microbicide 2010 Meeting, Pittsburgh, PA May 22-15, 2010.

 

571. A NEW MODEL FOR STUDIES ON CERVICOVAGINAL INFLAMMATION AND BARRIER DISRUPTION.

Blaskewicz1, C., Ayehunie2, S. and Anderson1, D. 1Boston University School of Medicine, Boston MA; 2MatTek Corp, Ashland, MA. Presented at Microbicide 2010 Conference, May 22-25, Pittsburg, PA.

 

555. PSORIASIN (S100A7) IS A MAJOR ANTIMICROBIAL COMPONENT OF THE FEMALE GENITAL TRACT.

Mildner1, M., Abtin1, A., Gmeiner1, R., Sam1, C., Gläser2, R., Schröder2, J-M., Mlitz1, V., Stichenwirth1, M., Pammer1, J., Geusau1, A., Tschachler1, E. 1Medical University of Vienna, Vienna, Austria 2University Hospital Schleswig-Holstein, Kiel, Germany. 37th Annual Meeting of the European Society for Dermatological Research, 5-8 September 2007, Zurich, Switzerland.

 

544. DISRUPTION OF TIGHT JUNCTIONS BY CELLULOSE SULFATE FACILITATES HIV INFECTION: MODEL OF MICROBICIDE SAFETY.

Mesquita1, P.M.M., Cheshenko1, N., Wilson1, S.S., Mhatre1, M., Guzman1, E., Fakioglu1, E., Keller3, M.J., and Herold1,2, B.C. Department of 1Pediatrics, 2Microbiology-Immunology, and 3Medicine, Albert Einstein College of Medicine, Bronx, New York. J Infectious Diseases, 200, 599–608 (2009).

 

540. REAWAKENING RETROCYCLINS: ANCESTRAL HUMAN DEFENSINS ACTIVE AGAINST HIV-1. (REPORT).

Venkataraman, N., Cole, A.L., Ruchala, P., Waring, A.J., Lehrer, R.I., Stuchlik, O., Pohl, J. and Cole, A.M. University of Massachusetts, Amherst, MA. PloS Biology, 7.4, 720(10) (2009).

 

523. PRE-VALIDATION OF RECONSTRUCTED EPIVAGINAL TISSUE MODEL TO SCREEN IRRITATION POTENTIAL OF CHEMICALS.

Ayehunie, S., Cannon, C., LaRosa, K., Hayden, P., and Klausner, M. MatTek Corporation, Ashland, MA, USA. Presented at Society of Toxicology Meeting, (2009).

 

492. SPERMICIDAL ACTIVITY OF THE SAFE NATURAL ANTIMICROBIAL PEPTIDE SUBTILOSIN.

Sutyak1, K.E., Anderson2, R.A., Dover1,3, S.E., Feathergill2, K.A., Aroutcheva2,4, A.A., Faro5, S., and Chikindas1,4, M.L. 1Department of Microbiology and Molecular Genetics and Department of Food Science, Rutgers, The State University of New Jersey, New Brunswick, NJ 08854-8097, USA. 2Department of Obstetrics and Gynecology, Rush University Medical Center, Chicago, IL 60612, USA. 3The Royal Institute of Technology, 100 44 Stockholm, Sweden. 4Health Promoting Naturals, Inc., Highland Park, NJ 08904, USA. 5The Women’s Hospital of Texas, Houston, TX 77054, USA. Infectious Diseases in Obstetrics and Gynecology, 540758, 2008.

 

480. REVERSIBLE DEFICIENCY OF ANTIMICROBIAL POLYPEPTIDES IN BACTERIAL VAGINOSIS.

Valore1, E.V., Wiley2, D.J., and Ganz1, T. Departments of Medicine and Pathology, 1David Geffen School of Medicine, and 2School of Nursing, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, California 90095-1690. Infection and Immunity, 5693–5702, Oct. (2006).

 

472. SAFETY STUDY OF AN ANTIMICROBIAL PEPTIDE LACTOCIN 160, PRODUCED BY THE VAGINAL LACTOBACILLUS RHAMNOSUS.

Dover1,2, S.E., Aroutcheva3,4, A.A., Faro5, S., and Chikindas2,4, M.L. 1School of Biotechnology, The Royal Institute of Technology, 100 44 Stockholm, Sweden. 2Rutgers, The State University of New Jersey, New Brunswick, NJ 08901-8520, USA. 3Rush Medical Center, Chicago, IL 60612, USA. 4Health Promoting Naturals, Inc., Highland Park, NJ 08904, USA. 5The Women’s Hospital of Texas, Houston, TX 77054, USA. Infect. Diseases in Obstetrics and Gynecology, Article ID#78248, (2007).

 

469. STUDIES ON VAGINAL INNATE IMMUNITY IN THE EPIVAGINAL MODEL.

Anderson1, D., Nadolski1, A., Xu1, C., Pudney1, J., Politch1, J., Viglianti1, G., Bowman1, F., Ayehunie2, S., and Klausner2, M. 1Boston University School of Medicine, Boston, MA and 2MatTek Corporation, Ashland, MA. Microbicides 2008.

 

468. PRECLINICAL EVALUATION OF LIME JUICE AS A TOPICAL MICROBICIDE CANDIDATE.

Fletcher1, P.S., Harman1, S.J., Boothe2, A.R., Doncel2, G.F. and Shattock1, R.J. 1St. George's University of London, UK and 2CONRAD, Eastern Virginia Medical School, USA Retrovirology, 5:3, (2008).

 

453. STUDIES ON VAGINAL INNATE IMMUNITY IN THE EPIVAGINAL MODEL SYSTEM.

Anderson, D., Xu, C., Pudney, J., Nadolski, A., Viglianti, G., Bowman, R., Ayehunie, S., and Klausner, M. MatTek Corporation, Ashland, MA, USA.

 

442. REGULATORY REQUIREMENTS FOR IN VITRO SYSTEMS TO MEET PERFORMANCE STANDARDS OVER TIME AS WELL AS DURING VALIDATION.

Klausner, M., Kubilus, J., Ayehunie, S., Hayden, P., Chua, G., Sheasgreen, J. MatTek Corporation, Ashland, MA 01721. Society of Toxicology 46th Annual Meeting, Charlotte, NC, Abstract 1524, (2007). The Toxicologist, 96, 1, 315 (2007).

 

431. THE RETROCYCLIN ANALOGUE RC-101 PREVENTS HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION OF A MODEL HUMAN CERVICOVAGINAL TISSUE CONSTRUCT.

Cole1, A.L., Herasimtschuk1, A., Gupta2, P., Waring3, A., Lehrer3, R., and Cole1, A.M. 1Department of Molecular Biology & Microbiology, Biomolecular Science Center, Burnett College of Biomedical Sciences at University of Central Florida, Orlando, FL, 2Department of Infectious Diseases and Microbiology, University of Pittsburgh, PA, and 3Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA. Immunology, (online edition), 23-Jan-2007.

 

430. TRICHOMONAS VAGINALIS LIPOPHOSPHOGLYCAN TRIGGERS A SELECTIVE UPREGULATION OF CYTOKINES BY HUMAN FEMALE REPRODUCTIVE TRACT EPITHELIAL CELLS.

Fichorova1, R., Trifonova1, R., Gilbert2, R., Costello3, C., Hayes4, G., Lucas4, J., and Singh4, B. 1Laboratory of Genital Tract Biology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; 2Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY; 3Mass Spectrometry Resource, Boston University School of Medicine, Boston, MA; and 4Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, NY. Infection and Immunity, 74, 10, 5773–5779, October (2006).

 

426. IRRITATION TESTING OF CONTRACEPTIVE AND FEMININE-CARE PRODUCTS USING EPIVAGINAL, AN IN VITRO HUMAN VAGINAL-ECTOCERVICAL TISSUE MODEL.

Ayehunie, S., Hayden, P., Cannon, C., Lamore, S., Klausner, M., Sheasgreen, J. MatTek Corporation, Ashland, MA. Presented at EUROTOX 2006, Cavtat and Dubrovnik, Croatia, September 20-24, (2006).

 

421. VISUALIZING INDIVIDUAL, FLUORESCENTLY TAGGED HIV-1 VIRIONS IN CERVICAL TISSUE.

Hope, T., Schmidt, T., Forde, E. Department of Cellular and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, IL. Presented at Microbicides 2006, Cape Town, South Africa, April 23-26, (2006).

 

420. BIOCOMPATIBILITY OF SOLID DOSAGE ANTI-HIV-1 MICROBICIDES AND VAGINAL PRODUCTS WITH THE MUCOSAL CYTOKINE NETWORK.

Trifonova, R., Pasicznyk, J-M., Fichorova, R. Laboratory of Genital Tract Biology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA. Antimicrobial Agents and Chemotherapy, 50, (12), 4005-4010, (2006).

 

418. EXPRESSION AND FUNCTION OF BACTERICIDAL/PERMEABILITY - INCREASING PROTEIN IN HUMAN GENITAL TRACT EPITHELIAL CELLS.

Canny1, G., Trifonova2, R., Kindelberger3, D., Colgan1, S., Fichorova2, R. 1Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women’s Hospital, Boston, MA, 2Laboratory of Genital Tract Biology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Boston, MA, 3Cytology Division and Women’s and Perinatal Pathology Division, Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. The Journal of Infectious Diseases, 194, 498-502, (2006).

 

411. CATIONIC POLYPEPTIDES ARE REQUIRED FOR ANTI-HIV-1-ACTIVITY OF HUMAN VAGINAL FLUID.

Venkataraman, N., Cole, A.L., Svoboda, P., Pohl, J., Cole, A.M. Biomolecular Science Center, University of Central Florida, Department of Molecular Biology and Microbiology, Orlando, FL. The Journal of Immunology, 2005, (175) 7560-7567 (2005).

 

388. ORGANOTYPIC HUMAN VAGINAL-ECTOCERVICAL TISSUE MODEL FOR IRRITATION STUDIES OF SPERMICIDES, MICROBICIDES, AND FEMININE-CARE PRODUCTS.

Ayehunie1, S., Cannon1, C., Lamore1, S., Kubilus1, J., Anderson2, B., Pudney2, J., Klausner1, M. 1MatTek Corporation, Ashland, MA, United States; 2Boston University School of Medicine, Boston, MA, United States. Toxicology in Vitro, 20, (5), 689-698, (2006).

 

376. HUMAN VAGINAL—ECTOCERVIAL TISSUE MODEL TO TEST THE IRRITATION POTENTIAL OF CONTRACEPTIVE AND VAGINAL-CARE PRODUCTS.

Ayehunie, S., Cannon, C., Lamore, S., Klausner, M., Sheasgreen, J., MatTek Corporation, Ashland, MA, USA. Presented at 5th World Congress, Berlin, Germany, August, (2005).

 

375. VAGINAL FORMULATION - HOW INNOCUOUS ARE THEY TO THE VAGINAL EPITHELIAL IMMUNE FUNCTION?

Trifonova, R.T., Pasicznyk, J.M., Fichorova, R.N. Harvard Medical School, Department of Obstetrics and Gynecology, Boston, M.A, USA. Presented at 25th Anniversary Meeting of the American Society of Reproductive Immunology, Providence, RI, June 16-18, 2005. American Journal of Reproductive Immunology, 54, (2), 121, (2005).

 

321. CONCORDANCE BETWEEN DIFFERENT IN VITRO CULTURE MODELS DESIGNED TO PREDICT VAGINAL IRRITATION AND/OR TOXICITY.

Watts, P., Nuttall1, J., Coplan1, P., Fairhurst1, D., Mitchnick1, M., and Shattock, R. St. George’s Hospital Medical School, London, UK, and 1International Partnership for Microbicides (IPM), Silver Spring, MD, USA. Presented at Microbicides 2004, London, England, March 28-31, (2004).

 

320. HUMAN VAGINAL-ECTOCERVICAL TISSUE MODEL FOR MICROBICIDE IRRITATION STUDIES.

Ayehunie1, S., Cannon1, C., Lamore1, S., Bellavance1, K., Kubilus1, J., LaBonte2, J., Owens2, C., Pudney3, J., Anderson2, D., Sodroski2, J., Klausner1, M. and Sheasgreen1, J. 1MatTek Corporation, Ashland, MA. 2Dana Farber Cancer Institute, Boston, MA. 3Brigham and Women’s Hospital, Boston, MA. Presented at Microbicides 2004, London, England, March 28-31, (2004).

 

312. EVALUATION OF RECONSTITUTED HUMAN VAGINAL EPITHELIUM AS A MODEL FOR DRUG DELIVERY OF FLUCONAZOLE GEL FOR TREATING VULVOVAGINAL CANDIDIASIS.

R. Elkeeb, M. Zdanowicz, and A. Belmonte. Massachusetts College of Pharmacy and Health Sciences, Boston, MA. Poster presented at the American Association of Pharmaceutical Scientists (AAPS), Salt Lake City, UT, October 26-30, (2003).

 

291. RECONSTRUCTED HUMAN VAGINAL-ECTOCERVICAL TISSUE MODELS.

Ayehunie1, S., Cannon1, C., Lamore1, S., Bellavance1, K., Kubilus1, J., LaBonte2, J., Pudney3, J., Anderson3, D., Sodroski2, J., and Klausner1, M. 1MatTek Corporation, Ashland, MA, 2Dana Farber Cancer Institute, and 3Brigham and Women Hospital, Boston, MA, USA. Presented at symposium entitled: "Topical Microbicides Development and Evaluation Workshop," The National Institute of Allergy and Infectious Diseases, The National Institutes of Health, Washington, D.C., Poster # A21, March 18-20, (2003).

 

266. ORGANOTYPIC ECTOCERVICO-VAGINAL TISSUE MODEL CONTAINING DENDRITIC CELLS.

Ayehunie1, S., Cannon1, C.L., Lamore1, S., Kubilus1, J., LaBonte2, J., Pudney3, J., Anderson3, D., Sodroski2, J., and Klausner1, M. 1MatTek Corporation, Ashland, MA 01721, 2Dana Farber Cancer Institute, and 3Brigham and Women's Hospital, Boston, MA, U.S.A. Presented at Microbicide 2002 Meeting, Antwerp, Belgium, May (2002).

 

255. HUMAN TISSUE MODEL FOR VAGINAL IRRITATION STUDIES.

Kubilus1, J., Cannon1, C.L., Klausner1, M., and Lonardo2, E.C. 1MatTek Corp., Ashland, MA., 2Johnson & Johnson, Personal Products Company, Skillman, NJ. The Toxicologist, 66 (1-S), 378, Soc. of Toxicol. (Reston, VA), Abstract #1848, (2002).

 

246. RECONSTRUCTION OF VAGINAL TISSUE MODEL FOR HIV INFECTION.

Ayehunie1, S., Cannon1, C.L., Kubilus1, J., Pudney2, J., LaBonte3, J., Anderson2, D., Sodroski3, J., and Klausner1, M. 1MatTek Corp., Ashland, MA 01721. 2Brigham and Womens Hospital, 3Dana Farber Cancer Institute, Boston, MA. Presented at Nobel Symposium No. 119, Global HIV Therapeutics - HIV Vaccines, Nobel Forum - Karolinska Instituet, Stockholm, Sweden, June 7-9, (2001).

 

 

 

www.MatTek.co.kr